Cart
sales@molnova.com
BC 11-38
CAS No. 686770-80-9
BC 11-38( —— )
Catalog No. M27479 CAS No. 686770-80-9
BC 11-38 is a potent, selective PDE biodepressant which is mainly effective against PDE11 (IC50 : 0.28 μM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 70 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 93 | In Stock |
|
| 25MG | 202 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 516 | In Stock |
|
| 200MG | 732 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBC 11-38
-
NoteResearch use only, not for human use.
-
Brief DescriptionBC 11-38 is a potent, selective PDE biodepressant which is mainly effective against PDE11 (IC50 : 0.28 μM).
-
DescriptionBC 11-38 is a potent, selective PDE biodepressant which is mainly effective against PDE11 (IC50 : 0.28 μM). (In Vitro):BC 11-38 ignificantly elevates cAMP levels and cortisol production in H295R human adenocarcinoma cells .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number686770-80-9
-
Formula Weight304.43
-
Molecular FormulaC15H16N2OS2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 33.33 mg/mL (109.48 mM)
-
SMILESO=C1C2=C(CCS2)N=C(SCCC)N1C3=CC=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.J Zhang , et al. Effect of steroidal saponins of Anemarrhenae rhizoma on superoxide generation in human neutrophils. Biochem Biophys Res Commun. 1999 Jun 16;259(3):636-9.
molnova catalog
related products
-
GSK-256066
A potent, selective PDE4 inhibitor with pIC50 of 11.5, 11.3, 11.4, and 11.9 for PDE4B, A, C, and D, respectively.
-
LJI308
LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
-
Mirodenafil
Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil (50 or 100 mg), obviously improved erectile function and was well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities.
